Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia

Inhibition of platelet production and mediated by antiplatelet antibodies is a well-known mechanism causing low platelet counts in immune thrombocytopenia (ITP). Use of thrombopoietin receptor agonists increases platelet counts and decreases the risk of bleeding in patients with ITP. Two such thromb...

Descripción completa

Detalles Bibliográficos
Autores principales: Vishnu, Prakash, Aboulafia, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888762/
https://www.ncbi.nlm.nih.gov/pubmed/27307776
http://dx.doi.org/10.2147/JBM.S80646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888762/
https://www.ncbi.nlm.nih.gov/pubmed/27307776
http://dx.doi.org/10.2147/JBM.S80646

Ejemplares similares